DS
RPRX icon

David Shaw’s Royalty Pharma RPRX Stock Holding History

David Shaw’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.4M Sell
525,114
-596,933
-53% -$31.1M 0.01% 1051
2026
Q1 		$53.8M Buy
1,122,047
+283,434
+34% +$12.4M 0.03% 628
2025
Q4 		$32.4M Buy
838,613
+698,585
+499% +$26.6M 0.02% 952
2025
Q3 		$4.94M Buy
140,028
+106,232
+314% +$3.85M ﹤0.01% 2214
2025
Q2 		$1.22M Sell
33,796
-242,043
-88% -$8.02M ﹤0.01% 3099
2025
Q1 		$8.59M Sell
275,839
-885,465
-76% -$28.1M 0.01% 1511
2024
Q4 		$29.6M Buy
1,161,304
+228,964
+25% +$6.07M 0.02% 811
2024
Q3 		$26.4M Buy
932,340
+898,728
+2,674% +$24.9M 0.02% 839
2024
Q2 		$886K Buy
+33,612
New +$932K ﹤0.01% 3270
2024
Q1 		– Sell
-13,387
Closed -$376K – 4673
2023
Q4 		$376K Sell
13,387
-384,459
-97% -$10.6M ﹤0.01% 3653
2023
Q3 		$10.8M Sell
397,846
-28,756
-7% -$854K 0.01% 1243
2023
Q2 		$13.1M Buy
426,602
+96,782
+29% +$3.28M 0.01% 1129
2023
Q1 		$11.9M Sell
329,820
-310,904
-49% -$11.5M 0.01% 1227
2022
Q4 		$25.3M Sell
640,724
-41,062
-6% -$1.71M 0.03% 772
2022
Q3 		$27.4M Buy
681,786
+530,538
+351% +$22.7M 0.03% 675
2022
Q2 		$6.36M Buy
151,248
+69,947
+86% +$2.87M 0.01% 1839
2022
Q1 		$3.17M Buy
+81,301
New +$3.19M ﹤0.01% 2831
2021
Q3 		– Sell
-54,095
Closed -$2.22M – 5190
2021
Q2 		$2.22M Buy
+54,095
New +$2.3M ﹤0.01% 2841

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's RPRX Position: Q2 2026 in Review

David Shaw reduced its Royalty Pharma (RPRX) stake by 53% in Q2 2026, selling an estimated $31.1M and leaving 525,114 shares worth $29.4M. The position accounts for 0.01% of the portfolio, ranked #1051.

David Shaw first reported a position in RPRX in Q2 2021 and has held it in 18 quarters since. The position peaked at $53.8M in Q1 2026. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • David Shaw held 525,114 shares of Royalty Pharma worth $29.4M as of Q2 2026.
  • David Shaw sold 596,933 Royalty Pharma shares in Q2 2026, an estimated $31.1M.
  • Royalty Pharma made up 0.01% of David Shaw's portfolio in Q2 2026, its #1051 holding.
  • David Shaw first reported a position in Royalty Pharma in Q2 2021 and has held it in 18 quarters since.
  • David Shaw's Royalty Pharma position peaked at $53.8M in Q1 2026.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.